Literature DB >> 23756199

Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model.

William Lee1, Reno C Reyes, Manoj K Gottipati, Karon Lewis, Mathieu Lesort, Vladimir Parpura, Michelle Gray.   

Abstract

Huntington's disease (HD) causes preferential loss of a subset of neurons in the brain although the huntingtin protein is expressed broadly in various neural cell types, including astrocytes. Glutamate-mediated excitotoxicity is thought to cause selective neuronal injury, and brain astrocytes have a central role in regulating extracellular glutamate. To determine whether full-length mutant huntingtin expression causes a cell-autonomous phenotype and perturbs astrocyte gliotransmitter release, we studied cultured cortical astrocytes from BACHD mice. Here, we report augmented glutamate release through Ca(2+)-dependent exocytosis from BACHD astrocytes. Although such release is usually dependent on cytosolic Ca(2+) levels, surprisingly, we found that BACHD astrocytes displayed Ca(2+) dynamics comparable to those in wild type astrocytes. These results point to a possible involvement of other factors in regulating Ca(2+)-dependent/vesicular release of glutamate from astrocytes. We found a biochemical footprint that would lead to increased availability of cytosolic glutamate in BACHD astrocytes: i) augmented de novo glutamate synthesis due to an increase in the level of the astrocyte specific mitochondrial enzyme pyruvate carboxylase; and ii) unaltered conversion of glutamate to glutamine, as there were no changes in the expression level of the astrocyte specific enzyme glutamine synthetase. This work identifies a new mechanism in astrocytes that could lead to increased levels of extracellular glutamate in HD and thus may contribute to excitotoxicity in this devastating disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Astrocytes; Glutamate; Huntington's disease; Pyruvate carboxylase

Mesh:

Substances:

Year:  2013        PMID: 23756199      PMCID: PMC3748209          DOI: 10.1016/j.nbd.2013.06.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  56 in total

Review 1.  Ca(2+) sources for the exocytotic release of glutamate from astrocytes.

Authors:  Vladimir Parpura; Vladimir Grubišić; Alexei Verkhratsky
Journal:  Biochim Biophys Acta       Date:  2010-11-27

2.  Imaging extracellular waves of glutamate during calcium signaling in cultured astrocytes.

Authors:  B Innocenti; V Parpura; P G Haydon
Journal:  J Neurosci       Date:  2000-03-01       Impact factor: 6.167

3.  1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.

Authors:  B G Jenkins; H D Rosas; Y C Chen; T Makabe; R Myers; M MacDonald; B R Rosen; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

4.  Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.

Authors:  J C Liévens; B Woodman; A Mahal; O Spasic-Boscovic; D Samuel; L Kerkerian-Le Goff; G P Bates
Journal:  Neurobiol Dis       Date:  2001-10       Impact factor: 5.996

Review 5.  Glutamate uptake.

Authors:  N C Danbolt
Journal:  Prog Neurobiol       Date:  2001-09       Impact factor: 11.685

6.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.

Authors:  R Lodi; A H Schapira; D Manners; P Styles; N W Wood; D J Taylor; T T Warner
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

Review 7.  Gliotransmission: Exocytotic release from astrocytes.

Authors:  Vladimir Parpura; Robert Zorec
Journal:  Brain Res Rev       Date:  2009-12-04

8.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

9.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

Authors:  Liliana Menalled; Bassem F El-Khodor; Monica Patry; Mayte Suárez-Fariñas; Samantha J Orenstein; Benjamin Zahasky; Christina Leahy; Vanessa Wheeler; X William Yang; Marcy MacDonald; A Jennifer Morton; Gill Bates; Janet Leeds; Larry Park; David Howland; Ethan Signer; Allan Tobin; Daniela Brunner
Journal:  Neurobiol Dis       Date:  2009-05-21       Impact factor: 5.996

10.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

Authors:  Xiaofeng Gu; Véronique M André; Carlos Cepeda; Shi-Hua Li; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  Mol Neurodegener       Date:  2007-04-30       Impact factor: 14.195

View more
  29 in total

Review 1.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

Review 2.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

3.  Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders.

Authors:  Alexei Verkhratsky; Vladimir Parpura
Journal:  Neurobiol Dis       Date:  2015-04-03       Impact factor: 5.996

4.  Stratification of astrocytes in healthy and diseased brain.

Authors:  Alexei Verkhratsky; Robert Zorec; Vladimir Parpura
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

Review 5.  Unravelling and Exploiting Astrocyte Dysfunction in Huntington's Disease.

Authors:  Baljit S Khakh; Vahri Beaumont; Roger Cachope; Ignacio Munoz-Sanjuan; Steven A Goldman; Rosemarie Grantyn
Journal:  Trends Neurosci       Date:  2017-05-31       Impact factor: 13.837

Review 6.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

7.  PATHOBIOLOGY OF NEURODEGENERATION: THE ROLE FOR ASTROGLIA.

Authors:  Alexei Verkhratsky; Robert Zorec; Jose J Rodriguez; Vladimir Parpura
Journal:  Opera Med Physiol       Date:  2016-03-04

8.  HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.

Authors:  Dagmar E Ehrnhoefer; Amber L Southwell; Meenalochani Sivasubramanian; Xiaofan Qiu; Erika B Villanueva; Yuanyun Xie; Sabine Waltl; Lisa Anderson; Anita Fazeli; Lorenzo Casal; Boguslaw Felczak; Michelle Tsang; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2018-01-15       Impact factor: 6.150

9.  Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model.

Authors:  Tara E Wood; Joshua Barry; Zhenquin Yang; Carlos Cepeda; Michael S Levine; Michelle Gray
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

10.  Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease.

Authors:  Ana María Estrada-Sánchez; Courtney L Burroughs; Stephen Cavaliere; Scott J Barton; Shirley Chen; X William Yang; George V Rebec
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.